期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

33例B细胞慢性淋巴细胞白血病免疫表型分析 被引量：3

Analysis the immunophenotyping of 33 chronic B lymphoid leukemia
暂未订购
导出
摘要 目的研究B细胞慢性淋巴细胞白血病(B-CLL)免疫表型特点。方法采用流式细胞术分析33例B-CLL的免疫表型。结果大部分B-CLL表达CD20、CD19、CD23、CD5、CD11c,仍有部分表达FMC7、CD22、CD43、CD38、κ轻链、λ轻链、ZAP-70。结论免疫表型分析是诊断慢性淋巴白血病(CLL)非常有用的依据。ZAP-70及CD38可以为B-CLL提供重要的预后信息,是两个较新颖的免疫测定指标。 Objective To investigate the immunophenotype characteristic of 33 B cell chronic lymphoid leukemia（B-CLL）.Methods Flow cytometry were used to analysis 33 cases of B-CLL.Results The B-CLL typically display composite phenotypes：CD20,CD19,CD22,CD23,CD5,CD11c,but the FMC7,CD43,CD38,κ light strand,λ light strand,ZAP-70 were variable present in some B-CLL cases.Conclusion Immunophenotypic analysis is an extremely useful adjunct in the diagnosis of chronic lymphoid leukemia.ZAP-70 and CD38 for B-CLL providing important prognostic information,are two relatively new immunoassay index.
作者 夏乐敏 翁香琴
机构地区 上海市中医医院血液科 上海瑞金医院血液学研究所
出处 《重庆医学》 CAS CSCD 北大核心 2011年第5期458-459,共2页 Chongqing medicine
关键词 白血病 淋巴样 免疫表型分型 流式细胞术 leukemia lymphoid immunophenotyping flow cytometry
分类号 R733.7 [医药卫生—肿瘤]
  • 相关文献

参考文献15

  • 1Kay NE,Hamblin TJ,Jelinek DF,et al.Chronic lymphocytic leukemia[J].Hematology,2002:193-213.
  • 2Durig J,Nuckl H,Crmer M,et al.ZAP-70 expression is a prognostic factor in chronic lymphoctytic leukaemia[J].Leukaemia,2003,17(12):2426-2434.
  • 3王欣,刘林,陈建斌,胡妮妮,王建渝,肖青.氟达拉滨联合环磷酰胺治疗慢性淋巴细胞白血病的临床研究[J].重庆医学,2009,38(10):1210-1212. 被引量：15
  • 4Jennings CD,Foon KA.Recent advances in flow cytometry:application to the diagnosis of hematologic malignancy[J].Blood,1997,90:2863-2892.
  • 5刘艳荣,常艳,王卉,于弘,高晖,陆道培,陈珊珊.慢性淋巴细胞系统白血病免疫表型分析[J].中华检验医学杂志,2003,26(1):17-21. 被引量：24
  • 6Damle RN,Ghiotto F,Valetto A.et al.B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated,antigen experienced B lymphocytes[J].Blood,2002,99(11):4087-4093.
  • 7Geisler CH,Larsen JK,Hansen NE,et al.Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia[J].Blood,1991,78(7):1795-1802.
  • 8Damle RN,Wasil T,Fais F,et al.IgVH gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia[J].Blood,1999,94(6):1840-1847.
  • 9Hamblin TJ,Davis Z,Gardiner A,et al.Unmutated IgV(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia[J].Blood,1999,94(6):1848-1854.
  • 10Stilgenbauer S,Bullinger L,Lichter P,et al.Genetics of chronic lymphocytic leukemia:genomic aberrations and IgV(H) gene mutation status in pathogenesis and clinical course[J].Leukemia,2002,16(6):993-1007.

二级参考文献13

  • 1刘红,江渝,陈幸华,孔佩艳,张怡,刘林,张曦,王庆余.氟达拉滨联合化疗药物治疗14例复发、难治性非霍奇金淋巴瘤临床疗效分析[J].重庆医学,2005,34(5):708-710. 被引量：5
  • 2Leporrier M,Chevret S,Cazin B, et al. Randomized comparison of fludarabine, CAP,and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients[J].Blood, 2001,98 : 2319.
  • 3French Cooperative Group on CLL. A randomized clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia[J].Blood, 1990,75 : 1422.
  • 4Barbara F, Eichhorst, Raymonde B,et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia[J].Blood, 2006,107 : 885.
  • 5Hansen MM, Andersen E, Birgens H, et al. CHOP versus chlorambucil/prednisone in chronic lymphocytic leukemia[J].Leuk Lymphoma, 1991,5(Suppl 1) : 97.
  • 6Keating M J, Estey E, O'Brien S, et al. Clinical experience with fludarabine in leukaemia[J].Drugs, 1994,47 (6) : 39.
  • 7OrBrien S, Kantarjian H,Beran M, et ai. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis derived prognostic model for response totreatment[J].Blood,1993,82:1695.
  • 8Adkins JC, Peters DH, Markham A. Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies[J].Drugs, 1997,53: 1005.
  • 9Keating MJ, O'Brien S, Lerner S, et al. Long term followup of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens asinitial therapy [J].Blood, 1998,92 : 1165.
  • 10Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia[J]. N Engl J Med, 2000,343 : 1750.

共引文献36

同被引文献53

  • 1姚建新,李建勇.126例慢性淋巴细胞白血病免疫表型分析[J].中国血液流变学杂志,2006,16(3):367-369. 被引量：6
  • 2吴雨洁,陈宝安,李建勇,徐卫,杨慧.慢性淋巴细胞白血病的免疫表型研究[J].现代医学,2007,35(2):129-132. 被引量：5
  • 3赵应斌,黎华莲,丁燕玲,刘纲毅.68例慢性白血病骨髓象分析[J].右江民族医学院学报,2007,29(5):710-712. 被引量：3
  • 4中国人民共和国卫生部医政司.全国临床检验操作规程[M].3版.南京:东南大学出版社,2006:246-266.
  • 5HARRIS N L,JAFFE E S,DIEBOLD J,et al.The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues:report of the Clinical Advisory Committee meeting-Airlie House,Virginia,November,1997[J].Hematol J,2000,1:53-66.
  • 6HUS I,PODHORECKA M,BOJARSKA-JUNAKA,et al.The clinical significance of ZAP-70and CD38expression in B-cell chronic lymphocytic leukaemia[J].Ann Oncol,2006,17:683-690.
  • 7OSCIER D G,GARDINER A C,MOULD S J,et al.Multivariate analysis of prognostic factors in CLL:clinical stage,IGVH gene mutational status,and loss or mutation of p53gene are independent prognostic factors[J].Blood,2002,100:1177-1184.
  • 8PAVLOVSKY C,PARDO L,PAVLOVSKY M A,et al.Is assessment of surface CD38expression worthwhile as a prognostic factor in chronic lymphocytic leukemia patients?[J].Hematology,2008,13:24-27.
  • 9Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors [J].Cun" Opin Immunol, 2009,21:215-223.
  • 10Savoldo B, Rooney CM, Di Stasi A, et al. Epstein Batv virus spe- cific cytotoxic T lymphocytes expressing the anti-CD30zeta arti- ficial chimeric T-cell receptor for immunotherapy of Hodgkin disease [J].Blood,2007,110(7):2620-2630.

引证文献3

二级引证文献16

重庆医学
2011年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部